Coming Soon: Free Wi-Fi From Google’s Sidewalk Labs
Google’s latest startup wants to use technology to improve city life.
Google is about to hit the streets with Sidewalk Labs, a Google startup that will focus on developing new technologies to improve urban life. Billing itself as an “urban innovation company,” Sidewalk Labs was founded to tackle urban problems such as housing, pollution, energy consumption, and transportation with the goal of making cities “more efficient, responsive, flexible and resilient.”
The first project? In New York City, LinkNYC will replace aging pay phones with slim, aluminum pillars that provide free high-speed Wi-Fi. The hubs also will allow people to charge their mobile devices and look up directions on touch screens. Qualcomm will be the wireless provider
Related: Why Google’s Internet Balloons May Be a $10 Billion Business
According to the Federal Communications Commission, 17 percent of the population, or 55 million people, in the United States don’t have access to high-speed broadband. Sidewalk Labs hopes that projects like LinkNYC can help bridge that gap.
For the LinkNYC initiative, Google acquired and merged two companies -- Control Group and Titan -- into a new venture called Intersection, which aims to provide free, public Wi-Fi in cities around the world using such familiar urban infrastructure as bus stops and pay phones.
Related: Google Spends More Than Any Other Tech Giant to Influence Congress
Daniel L. Doctoroff, a former Bloomberg CEO and deputy mayor for New York City, has been tapped to head Sidewalk Labs. Doctoroff, who conceived the idea for Sidewalk Labs with a Google team headed by CEO Larry Page, told Wired, “The vision really is to make cities connected places where you can walk down any street and have access to free ultra high speed Wi-Fi. The possibilities from there are just endless.”
Just don’t give us any automated, self-driving taxis, please.
Tax Refunds Rebound
Smaller refunds in the first few weeks of the current tax season were shaping up to be a political problem for Republicans, but new data from the IRS shows that the value of refund checks has snapped back and is now running 1.3 percent higher than last year. The average refund through February 23 last year was $3,103, while the average refund through February 22 of 2019 was $3,143 – a difference of $40. The chart below from J.P. Morgan shows how refunds performed over the last 3 years.
Number of the Day: $22 Trillion
The total national debt surpassed $22 trillion on Monday. Total public debt outstanding reached $22,012,840,891,685.32, to be exact. That figure is up by more than $1.3 trillion over the past 12 months and by more than $2 trillion since President Trump took office.
Chart of the Week: The Soaring Cost of Insulin
The cost of insulin used to treat Type 1 diabetes nearly doubled between 2012 and 2016, according to an analysis released this week by the Health Care Cost Institute. Researchers found that the average point-of-sale price increased “from $7.80 a day in 2012 to $15 a day in 2016 for someone using an average amount of insulin (60 units per day).” Annual spending per person on insulin rose from $2,864 to $5,705 over the five-year period. And by 2016, insulin costs accounted for nearly a third of all heath care spending for those with Type 1 diabetes (see the chart below), which rose from $12,467 in 2012 to $18,494.
Chart of the Day: Shutdown Hits Like a Hurricane
The partial government shutdown has hit the economy like a hurricane – and not just metaphorically. Analysts at the Committee for a Responsible Federal Budget said Tuesday that the shutdown has now cost the economy about $26 billion, close to the average cost of $27 billion per hurricane calculated by the Congressional Budget Office for storms striking the U.S. between 2000 and 2015. From an economic point of view, it’s basically “a self-imposed natural disaster,” CRFB said.
Chart of the Week: Lowering Medicare Drug Prices
The U.S. could save billions of dollars a year if Medicare were empowered to negotiate drug prices directly with pharmaceutical companies, according to a paper published by JAMA Internal Medicine earlier this week. Researchers compared the prices of the top 50 oral drugs in Medicare Part D to the prices for the same drugs at the Department of Veterans Affairs, which negotiates its own prices and uses a national formulary. They found that Medicare’s total spending was much higher than it would have been with VA pricing.
In 2016, for example, Medicare Part D spent $32.5 billion on the top 50 drugs but would have spent $18 billion if VA prices were in effect – or roughly 45 percent less. And the savings would likely be larger still, Axios’s Bob Herman said, since the study did not consider high-cost injectable drugs such as insulin.
